|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02616 CSTONE PHARMA-B
Nominal 
4.650 0.000 (0.000%) | 2022/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | 2018/12 RMB(K¥) | |
| Turnover | 481,363 | 97.508% | 243,718 | 1,038,832 | 0 | 0 |
| Cost of Sales | (202,985) | 90.004% | (106,832) | (241,421) | -- | -- |
| Gross Profit | 278,378 | 103.365% | 136,886 | 797,411 | -- | -- |
| 2022/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | 2018/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | (17,638) | (30,459) | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | (902,678) | -52.988% | (1,920,100) | (1,220,999) | (2,308,444) | (1,793,129) | |
| Taxation | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 0 | -- | 0 | 0 | 0 | 47,852 | |
| Others | -- | -- | -- | -- | 239,704 | 1,275,447 | |
| Profit / (Loss) Attributable to Shareholders | (902,678) | -52.988% | (1,920,100) | (1,220,999) | (2,068,740) | (469,830) | |
| 2022/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | 2018/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (1,195) | -84.195% | (7,561) | (22,841) | (66,984) | (7,947) |
| Depreciation & Amortisation | 44,540 | 96.549% | 22,661 | 14,801 | 11,580 | 5,266 |
| Directors' Emoluments | 83,640 | -30.703% | 120,698 | 164,101 | 167,245 | 141,294 |
| 2022/12 - Final | %Chg (Compare to Final) | 2021/12 | 2020/12 | 2019/12 | 2018/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2022/12 - Final | %Chg (Compare to Final) | 2021/12 | 2020/12 | 2019/12 | 2018/12 | |
| EPS (cts) | -77.000 | -53.333% | -165.000 | -117.000 | -239.000 | -279.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | (0.521) | -- | (1.274) | (0.486) | (1.247) | (4.693) |
| NBV per share ($) | 0.375 | -- | 1.017 | 2.516 | 2.414 | -- |
| Remarks: | Real time quote last updated: 13/06/2025 08:44 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (¥) | RMB -91,207,000 |
| %Change | -75.164% |
| EPS / (LPS) | RMB -0.070 |
| NBV Per Share (¥) | RMB 0.283 |